Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label dose-escalation and dose-expansion study of HX008 + MRG003 in EGFR-positive advanced or metastatic solid tumors
CTR20221106Phase 2Active
- Sponsor
- Hangzhou Miracogen
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pucotenlimab and becotatug vedotin in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 1 more, sponsored by Hangzhou Miracogen. Primary endpoints: Maximum tolerated dose, Recommended phase II dose and 1 more. Started Jun 2022; status: active.
02
Drugs
pucotenlimabbecotatug vedotin
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20221106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221106.